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ENOXAPARIN — A PHARMACOECONOMIC 
REVIEW OF ITS USE IN THROMBOEMBOLIC 
PROPHYLAXIS
Cal ML1, Fabre N2, Cal JC2
1Université Victor Segalen Bordeaux 2, Bordeaux cedex, 
France; 2J2C Santé, Mérignac, France
OBJECTIVE: Enoxaparin is a low-molecular-weight hep-
arin widely used in the prophylaxis and treatment of
venous thromboembolism. This study critically reviews
recent literature to determine the clinical conditions for
which enoxaparin can be considered as a gold standard
treatment from both outcome and cost standpoints.
METHODS: A Medline and current contents search for
published pharmacoeconomic evaluations, from 1980 to
present, was conducted. Abstracts were excluded. A large
range of cost-effectiveness and cost-utility analyses were
available, mainly comparing enoxaparin with unfraction-
ated heparin (UFH) and warfarin, and taking into ac-
count the different dosage regimens (30 mg, 40 mg once
or twice daily) currently recommended for durations
ranging from 5 days to 3 months. Efficiency was often in-
vestigated on the basis of decision trees setting out clini-
cal alternatives and probable events: deep vein thrombo-
sis (DVT); pulmonary embolism (PE); major bleed; death.
Clinical outcome data were extracted from selected ran-
domized, controlled trials or meta-analyses. In most
cases, direct costs were only estimated.
RESULTS: Enoxaparin was shown to be more efficient than
UFH in the treatment of acute DVT in the hospital setting
than warfarin for the short-term prophylaxis of throm-
boembolism in inpatients undergoing knee or hip replace-
ment. Long-term enoxaparin therapy for outpatients was
associated with better cost-effectiveness or cost-utility ratios
than enoxaparin treatment in elective hip surgery. More-
over, enoxaparin emerged as a dominant strategy versus
UFH therapy, yielding overall cost savings in outpatient ex-
tended prophylaxis for hip surgery; in general surgery and
in outpatient treatment of acute proximal DVT.
CONCLUSION: There is now strong clinical and economic
evidence that enoxaparin may be more effective than war-
farin and UFH, perhaps safer than UFH, while reducing
short-term costs of thromboembolic events but also the sub-
stantial long-term costs of post-thrombotic complications.
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ASSESSING THE IMPACT OF HYPERLIPIDEMIA 
TREATMENT WITH PRAVASTATIN AND 
SIMVASTATIN IN A LARGE 
COUNTY INSTITUTION
Walker CL1, Milton-Brown J2, Henry A2, Lal LS1
1Texas Southern University, Houston, TX, USA; 2Drug 
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OBJECTIVE: The purpose of this study is to evaluate if a
sample county-hospital population has achieved target
cholesterol values, per National Cholesterol Education
Program (NCEP) guidelines while on pravastatin or simv-
astatin therapy.
METHODS: A chart review of patients from eleven
health-care facilities within the county was obtained for
evaluation of current total cholesterol (TC), low density
lipoprotein (LDL), high density lipoprotein (HDL) and
triglyceride levels. The inclusion criteria consisted of pa-
tients who had undergone HMG-CoA reductase inhibitor
therapy for at least six months. They were retrospectively
evaluated to determine impact on lipid profile. Data col-
lection included demographics such as, gender, race, and
risk factors, in addition to the standard lipid profile.
RESULTS: Results are being reported for the initial 120
patients evaluated. On the average, post-treatment TC
and LDL levels are 219 mg/dl and 136 mg/dl, respec-
tively, in the sample population. Results indicate that
only about 36% of the patients have reached target TC
and LDL levels per NCEP guidelines while 64% of the
patients were above target levels. Of the two agents eval-
uated, 75% of the patients on pravastatin reached treat-
ment goals while only 26% of the patients on simvastatin
reached treatment goals. African-Americans, after treat-
ment, had the highest TC and LDL values. Overall, the
patients had an average of three risk factors.
CONCLUSION: The preliminary study results indicate
that a high percentage of county hospital patients have
TC values  200 mg/dl and LDL values 130 mg/dl,
even after therapy with an HMG-CoA reductase inhibi-
tor. Patients with more than two risk factors and a LDL
level greater than 130 mg/dl must be targeted for more
aggressive pharmacotherapeutic management and be en-
couraged to make necessary lifestyle changes. Additional
studies are needed to determine the effect of different
pharmacological agents and ethnic influences on out-
come.
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IMPACT OF NON-COMPLIANCE ON THE COST-
EFFECTIVENESS OF STATIN THERAPY
Hughes DA, Bagust A
University of Liverpool, Liverpool, UK
OBJECTIVES: Non-compliance is a major problem in
clinical practice and often leads to sub-optimal therapeu-
tic response. This is particularly evident when effective
treatment is available for a chronic, asymptomatic dis-
ease. In the present study, an evaluation of the impact of
non-compliance on the clinical efficacy of antihyperlipi-
daemic drugs is made.
METHODS: An electronic search of the literature was
conducted in order to identify trials and other reports
that presented compliance data and clinical endpoints
(reduction in LDL cholesterol). Assuming a class effect
for the actions of HMG-CoA reductase inhibitors (stat-
ins), estimates of cost-effectiveness (cost per percentage
reduction in LDL cholesterol) were made for individual
drugs at the different compliance rates.
